Bristol-Myers Squibb Company (VIE:BMYS)
Austria · Delayed Price · Currency is EUR | Market Cap | 105.91B -7.6% |
| Revenue (ttm) | 41.05B -0.2% |
| Net Income | 6.01B |
| EPS | 2.95 |
| Shares Out | n/a |
| PE Ratio | 17.63 |
| Forward PE | 9.47 |
| Dividend | 2.15 (4.18%) |
| Ex-Dividend Date | Jan 2, 2026 |
| Volume | n/a |
| Average Volume | 1 |
| Open | 51.67 |
| Previous Close | 51.63 |
| Day's Range | 51.67 - 51.67 |
| 52-Week Range | 36.69 - 56.67 |
| Beta | n/a |
| RSI | 53.65 |
| Earnings Date | Apr 30, 2026 |
About VIE:BMYS
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for oncology, hematology, immunology, cardiovascular, neuroscience, and other areas. The company’s products include Opdivo for various anti-cancer indications; Opdivo Qvantig, a subcutaneous PD-1 inhibitor for solid tumorsr; Orencia for active rheumatoid arthritis and psoriatic arthritis; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Reblozyl to treat ... [Read more]
News
Bristol Myers Squibb Announces Positive Phase 3 Results from the SUCCESSOR-2 Study of Oral Mezigdomide in Relapsed or Refractory Multiple Myeloma
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #CELMoD--Bristol Myers Squibb Announces Positive Phase 3 Data from the SUCCESSOR-2 Study of Oral Mezigdomide in Relapsed or Refractory Multiple Myeloma.
U.S. FDA Approves Bristol Myers Squibb's Sotyktu® (deucravacitinib) for the Treatment of Adults with Active Psoriatic Arthritis
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #FDA--U.S. FDA Approves Bristol Myers Squibb's Sotyktu® (deucravacitinib) for the Treatment of Adults with Active Psoriatic Arthritis.
Bristol Myers Squibb Announces Dividend
PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb Announces Dividend.
SystImmune and Bristol Myers Squibb Highlight Positive Phase III Interim Topline Results for izalontamab brengitecan (Iza-bren) in Previously Treated Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer
REDMOND, Wash. & PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #Patients--SystImmune and BMS Highlight Positive Phase III Interim Topline Results for izalontamab brengitecan (Iza-bren) in Previously-Treat...
NYSE Content Update: Two MSCI Indexes to Begin Trading on NYSE Arca Options
NYSE issues a pre-market daily advisory direct from the trading floor. NEW YORK, Feb. 25, 2026 /PRNewswire/ -- The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the N...
Bristol Myers Squibb to Participate in the TD Cowen 46th Annual Health Care Conference
PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb to Participate in the TD Cowen 46th Annual Health Care Conference.
Bristol Myers Squibb Announces Positive Top-Line Results from Registrational Phase 2 Study of Luspatercept in Adults with Alpha (α)-Thalassemia
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #BMS--Bristol Myers Squibb Announces Positive Top-Line Results from Registrational Phase 2 Study of Luspatercept in Adults with Alpha (α)-Thalassemia.
U.S. Food and Drug Administration Accepts Bristol Myers Squibb's New Drug Application for Iberdomide in Patients with Relapsed or Refractory Multiple Myeloma
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #BMS--U.S. Food and Drug Administration Accepts Bristol Myers Squibb's New Drug Application for Iberdomide in Relapsed or Refractory Multiple Myeloma.
Evinova and Bristol Myers Squibb Forge Strategic Collaboration to Optimize Clinical Development with Artificial Intelligence
BAAR, Switzerland--(BUSINESS WIRE)--Evinova and Bristol Myers Squibb Forge Strategic Collaboration to Optimize Clinical Development with Artificial Intelligence.
Bristol Myers Squibb CEO: Richest product pipeline we've had in the last decade
Chris Boerner, Bristol Myers Squibb CEO, joins CNBC's "Power Lunch" to discuss the company's quarterly earnings results, the drug pipeline and much more.
Dow Tumbles Over 400 Points; Bristol Myers Reports Strong Q4 Results
Bristol Myers Squibb & Co. (NYSE:BMY) reported better-than-expected results for the fourth quarter.
Bristol Myers Flags Data-Rich 2026 After Solid Quarter
Bristol Myers Squibb & Co. (NYSE: BMY) reported fourth-quarter 2025 revenues of $12.50 billion on Thursday, beating the consensus of $12.281 billion, a 1% increase year over year.
Bristol Myers Stock Rises. Why Fourth-Quarter Earnings Are Exciting Investors.
Bristol Myers Squibb issues an especially upbeat outlook for 2026.
Bristol Myers Squibb Revenue Ticks Up on Immuno-Oncology Growth
Bristol Myers Squibb reported higher fourth-quarter revenue as growth in sales of its immuno-oncology treatments helped to offset a decline in revenue for some of its older drugs.
Bristol Myers forecasts upbeat 2026, expecting Eliquis price cut to pay off
Bristol Myers Squibb on Thursday forecast 2026 results above Wall Street estimates, saying that price cuts to its blood thinner Eliquis will help drive up revenue.
Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2025
PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2025.
OXB Signs New Multi-Year Commercial Supply Agreement with Bristol Myers Squibb
Oxford, UK – 4 February 2026: OXB (LSE: OXB), a global quality and innovation-led cell and gene therapy CDMO, today announces it has expanded its strategic partnership with Bristol Myers Squibb (“BMS”...
Bristol Myers Squibb Teams Up with Kasey Keller to Share His Lymphoma Journey with Breyanzi
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #Breyanzi--Bristol Myers Squibb Teams Up with Kasey Keller to Share His Lymphoma Journey with Breyanzi.
Bristol Myers Squibb Introduces "Change the Target. Change What's Possible.
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #FXIa--Bristol Myers Squibb Introduces "Change the Target. Change What's Possible.” to Highlight Unmet Needs in Cardiovascular and Thromboembolic Care.
Janux Therapeutics Strikes Bristol Myers Biotech Deal Worth $800 Million
Janux Therapeutics, Inc. (NASDAQ: JANX) on Thursday announced a collaboration and exclusive worldwide license agreement with Bristol Myers Squibb Co. (NYSE: BMY).
Janux Therapeutics, Bristol Myers enter up to $850 million deal to develop cancer drug
Janux Therapeutics said on Thursday it has entered a collaboration with Bristol Myers Squibb to develop a new cancer treatment, sending its shares up more than 12% in premarket trading.
Final Trade: BMY, IGV, SOXX, GEN, AMZN
The final trades of the day with CNBC's Melissa Lee and the 'Fast Money' traders.
2 Top Blue-Chip Stocks to Buy and Hold in 2026
The undervalued stocks of these reliable large companies look attractive today.
Bristol Myers partners with Microsoft for AI-driven lung cancer detection
Bristol Myers Squibb said on Tuesday it had signed an agreement with Microsoft to use the tech company's AI-enabled radiology platform to help speed up early detection of lung cancer.